New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets without original empirical data or systematic search methodology
PubMed 23406187 · doi:10.4149/bll_2013_037
What was done
This paper is a narrative review examining the role of high-density lipoprotein (HDL) and reverse cholesterol transport in atherogenesis and cardiovascular disease risk, focusing on therapeutic strategies to raise HDL alongside standard statin therapy.
What was found
The abstract reports no quantitative data, statistics, or original empirical measurements. It describes that low HDL levels remain an independent risk factor for cardiovascular disease despite statin-mediated low-density lipoprotein (LDL) reduction, and notes that HDL directly promotes cholesterol efflux from foam cells within atherosclerotic lesions.
Why it matters
It highlights reverse cholesterol transport as a key biological mechanism in atherosclerosis and outlines the rationale for exploring HDL-targeted adjunctive therapies to address residual cardiovascular risk.
Limits
The abstract provides no original trial data, sample sizes, or quantitative effect sizes. As an unsystematic narrative review citing 26 references, it is vulnerable to selection bias and reflects expert conceptual framing rather than direct clinical efficacy evidence.
Cited by
- contradicts HDL particles can penetrate the inner layer of the arterial wall, bind to LDL, absorb cholesterol and triglycerides, and transport them back to the liver.